Oxurion NV (OXUR.BR)
EUR 0.1
(1.11%)
EUR 0.1
(1.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -12.11 Million EUR | 46.84% |
| 2022 | -22.77 Million EUR | 20.6% |
| 2021 | -28.68 Million EUR | 3.59% |
| 2020 | -29.75 Million EUR | 21.5% |
| 2019 | -37.9 Million EUR | 3.4% |
| 2018 | -39.24 Million EUR | -33.12% |
| 2017 | -29.47 Million EUR | 13.92% |
| 2016 | -34.24 Million EUR | 12.0% |
| 2015 | -38.91 Million EUR | 26.17% |
| 2014 | -52.71 Million EUR | -306.63% |
| 2013 | 25.51 Million EUR | -12.34% |
| 2012 | 29.1 Million EUR | 217.48% |
| 2011 | -24.77 Million EUR | -268.98% |
| 2010 | 14.66 Million EUR | -2.18% |
| 2009 | 14.98 Million EUR | 41.56% |
| 2008 | 10.58 Million EUR | -39.21% |
| 2007 | 17.41 Million EUR | 67.05% |
| 2006 | 10.42 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.31 Million EUR | 0.0% |
| 2023 Q2 | -7.88 Million EUR | 0.0% |
| 2023 Q4 | -5.05 Million EUR | 0.0% |
| 2023 FY | -12.11 Million EUR | 46.84% |
| 2022 FY | -22.77 Million EUR | 20.6% |
| 2022 Q2 | -13.74 Million EUR | 0.0% |
| 2022 Q4 | -9.03 Million EUR | 0.0% |
| 2021 Q2 | -15.4 Million EUR | 0.0% |
| 2021 Q4 | -13.2 Million EUR | 0.0% |
| 2021 FY | -28.68 Million EUR | 3.59% |
| 2020 FY | -29.75 Million EUR | 21.5% |
| 2020 Q4 | -15.78 Million EUR | 0.0% |
| 2020 Q2 | -13.48 Million EUR | 0.0% |
| 2019 Q2 | -18.19 Million EUR | 0.0% |
| 2019 Q4 | -19.1 Million EUR | 0.0% |
| 2019 FY | -37.9 Million EUR | 3.4% |
| 2018 Q2 | -15.66 Million EUR | 0.0% |
| 2018 Q4 | -23.57 Million EUR | 0.0% |
| 2018 FY | -39.24 Million EUR | -33.12% |
| 2017 Q4 | -14.46 Million EUR | 0.0% |
| 2017 FY | -29.47 Million EUR | 13.92% |
| 2017 Q2 | -15.01 Million EUR | 0.0% |
| 2016 Q4 | -19.26 Million EUR | 0.0% |
| 2016 Q2 | -14.98 Million EUR | 0.0% |
| 2016 FY | -34.24 Million EUR | 12.0% |
| 2015 FY | -38.91 Million EUR | 26.17% |
| 2015 Q4 | -19.12 Million EUR | 0.0% |
| 2015 Q2 | -19.78 Million EUR | 0.0% |
| 2014 Q4 | -28.3 Million EUR | 0.0% |
| 2014 Q2 | -24.41 Million EUR | 0.0% |
| 2014 FY | -52.71 Million EUR | -306.63% |
| 2013 Q2 | 54.07 Million EUR | 0.0% |
| 2013 Q4 | -28.56 Million EUR | 0.0% |
| 2013 FY | 25.51 Million EUR | -12.34% |
| 2012 Q1 | 7.61 Million EUR | 0.0% |
| 2012 FY | 29.1 Million EUR | 217.48% |
| 2012 Q4 | 6.61 Million EUR | -13.25% |
| 2012 Q2 | 7.61 Million EUR | 0.0% |
| 2012 Q3 | 7.61 Million EUR | 0.0% |
| 2011 Q4 | 7.61 Million EUR | 240.86% |
| 2011 Q1 | -5.4 Million EUR | 0.0% |
| 2011 Q2 | -5.4 Million EUR | 0.0% |
| 2011 FY | -24.77 Million EUR | -268.98% |
| 2011 Q3 | -5.4 Million EUR | 0.0% |
| 2010 FY | 14.66 Million EUR | -2.18% |
| 2010 Q2 | -3.42 Million EUR | 0.0% |
| 2010 Q1 | -3.42 Million EUR | 0.0% |
| 2010 Q3 | -3.42 Million EUR | 0.0% |
| 2010 Q4 | -5.4 Million EUR | -57.77% |
| 2009 Q1 | -3.41 Million EUR | 0.0% |
| 2009 FY | 14.98 Million EUR | 41.56% |
| 2009 Q3 | -3.41 Million EUR | 0.0% |
| 2009 Q2 | -3.41 Million EUR | 0.0% |
| 2009 Q4 | -3.42 Million EUR | -0.39% |
| 2008 Q4 | -3.41 Million EUR | -210.73% |
| 2008 FY | 10.58 Million EUR | -39.21% |
| 2008 Q1 | 3.08 Million EUR | 0.0% |
| 2008 Q2 | 3.08 Million EUR | 0.0% |
| 2008 Q3 | 3.08 Million EUR | 0.0% |
| 2007 Q3 | -4.35 Million EUR | 0.0% |
| 2007 Q4 | 3.08 Million EUR | 170.83% |
| 2007 FY | 17.41 Million EUR | 67.05% |
| 2007 Q2 | -4.35 Million EUR | 0.0% |
| 2007 Q1 | -4.35 Million EUR | 0.0% |
| 2006 Q4 | -4.35 Million EUR | -72.04% |
| 2006 FY | 10.42 Million EUR | 0.0% |
| 2006 Q3 | -2.53 Million EUR | 0.0% |
| 2006 Q2 | -2.53 Million EUR | 0.0% |
| 2006 Q1 | -2.53 Million EUR | 0.0% |
| 2005 Q4 | -2.53 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Nicox S.A. | -17.5 Million EUR | 30.812% |
| European Medical Solutions | -135 Thousand EUR | -8870.37% |
| FERMENTALG | -11.8 Million EUR | -2.558% |
| argenx SE | -417.15 Million EUR | 97.097% |
| BioSenic S.A. | -7.04 Million EUR | -72.017% |
| Celyad Oncology SA | -8.45 Million EUR | -43.195% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 24.279% |
| Onward Medical N.V. | -35.46 Million EUR | 65.852% |
| PHAXIAM Therapeutics S.A. | -23.66 Million EUR | 48.817% |
| Financière de Tubize SA | -2.14 Million EUR | -464.839% |
| UCB SA | 604 Million EUR | 102.005% |